Diffuse Lung Disease
-
Get informed and involved with smoking cessation strategies, advocacy
Sessions will equip attendees with the latest information about the health consequences of e-cigarettes and cannabis. Because the landscape has evolved so much recently, misconceptions are common—even among clinicians, said Evan Stepp, MD, FCCP.
-
ORCA-3 replicates strong tobacco cessation results for cytisinicline
The ORCA-3 trial demonstrated that cytisinicline, a reformulated compound, significantly outperformed placebo by nearly six times in helping adults who smoke to quit.
-
Update on the evaluation and management of interstitial lung abnormalities
New guidelines from ATS outline the screening and follow-up procedures for interstitial lung abnormalities as well as define who is at higher risk for progressing to ILD.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Fernando Martinez, MD, FCCP, said he expects the treatment options for fibrotic lung disease will soon become more complex—in a good way—as more effective therapies become available.
-
GOLDen handcuffs: Beyond spirometry in COPD
When it comes to diagnosing COPD, clinicians must look beyond spirometry and physiology to see a patient fully.
-
Newest Bridging Specialties program focuses on team-based care in PH-ILD
The Bridging Specialties®: Timely Diagnosis for PH-ILD program encourages collaboration across disciplines and provides assets designed for practical use.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
-
Delving deeper into the molecular genetics of idiopathic pulmonary fibrosis
William Whalen II, MD, MS, reflects on his experience as a recipient of the 2023 CHEST Research Grant in Pulmonary Fibrosis and how it has affected his professional trajectory.
-
TETON trials could herald multimodal approach to IPF
Steven Nathan, MD, said the addition of inhaled treprostinil would offer a novel approach that would allow clinicians to target the disease on two fronts.
-
Incorporating climate-related events into clinical practice
Review six steps a pulmonary clinician can take prior to a climate-related event to prepare for a potential disaster scenario and mitigate patient risk.
-
Parkinson’s drug shows promise as treatment for nicotine addiction in mouse model
Tobacco cessation expert, Carolyn Dresler, MD, MPA, said new evidence of cross talk between different types of acetylcholinergic receptors could be an important step for future research to determine if, and at what doses, these results could be replicated in humans.
-
Corticosteroid benefits unclear for acute ILD exacerbations
Erin Meier, MD, and Rachana Krishna, MBBS, MSCR, discuss the clinical implications of a recent meta-analysis, which suggests steroids may not help all patients with interstitial lung disease (ILD) who experience a flare.
